Cognition Therapeutics (NASDAQ:CGTX) Price Target Raised to $6.00

Cognition Therapeutics (NASDAQ:CGTX) had its price objective hoisted by HC Wainwright from $5.00 to $6.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Chardan Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.30.

Cognition Therapeutics Stock Down 0.6 %

CGTX opened at $0.63 on Thursday. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The business’s 50 day moving average is $0.48 and its two-hundred day moving average is $0.92. The firm has a market cap of $26.18 million, a price-to-earnings ratio of -0.65 and a beta of 1.26.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the period. CM Management LLC raised its position in Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares during the last quarter. Sigma Planning Corp lifted its stake in shares of Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after acquiring an additional 25,050 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at about $27,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.